PinnyPeptide

MOTS-c vs SS-31 (Elamipretide)

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

MOTS-c

Longevity

Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis.

Peptide B

SS-31 (Elamipretide)

Longevity

Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin.

Typical vial

5 mg

Typical dose

5000-10000 mcg

Half-life

Not well characterized in humans (estimated hours based on peptide size)

FDA status

Not FDA approved. Investigational compound with no clinical …

Typical vial

5 mg

Typical dose

5000-50000 mcg

Half-life

~4 hours

FDA status

Not FDA approved. FDA declined approval for Barth syndrome i…

MOTS-c effects

  • Activates AMPK pathway to enhance metabolic homeostasis
  • Improves insulin sensitivity and glucose uptake
  • Promotes fatty acid oxidation and reduces fat accumulation
  • Mimics exercise-induced metabolic adaptations
  • Preserves skeletal muscle function during aging
  • Enhances mitochondrial biogenesis and function

SS-31 (Elamipretide) effects

  • Stabilizes cardiolipin at the mitochondrial inner membrane
  • Restores electron transport chain efficiency and ATP production
  • Reduces mitochondrial ROS production at the source
  • Protects against ischemia-reperfusion injury in heart and kidney
  • Improves age-related mitochondrial dysfunction

MOTS-c side effects

  • Injection site reactions (redness, mild pain)
  • Transient changes in blood glucose levels
  • Mild fatigue during initial dosing
  • Limited human safety data available

SS-31 (Elamipretide) side effects

  • Injection site reactions (pain, redness)
  • Mild headache
  • Transient flushing
  • Occasional dizziness

MOTS-c dosing ranges

Metabolic optimization and longevity

5-10 mg · Three to five times weekly (SubQ) · 4-8 weeks

SS-31 (Elamipretide) dosing ranges

Mitochondrial support and longevity

5-50 mg · Once daily (SubQ) · 4-12 weeks

Full MOTS-c guide → Full SS-31 (Elamipretide) guide →

MOTS-c vs SS-31 (Elamipretide) — common questions

What is the difference between MOTS-c and SS-31 (Elamipretide)?

MOTS-c: Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis. Typical dose 5000-10000 mcg. SS-31 (Elamipretide): Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin. Typical dose 5000-50000 mcg. Both fall under the Longevity category.

Can you stack MOTS-c and SS-31 (Elamipretide)?

Stacking MOTS-c with SS-31 (Elamipretide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, MOTS-c or SS-31 (Elamipretide)?

MOTS-c is typically dosed: Three to five times weekly (SubQ) for Metabolic optimization and longevity. SS-31 (Elamipretide) is typically dosed: Once daily (SubQ) for Mitochondrial support and longevity.

Are MOTS-c and SS-31 (Elamipretide) FDA approved?

MOTS-c: Not FDA approved. Investigational compound with no clinical trials completed for regulatory submission. SS-31 (Elamipretide): Not FDA approved. FDA declined approval for Barth syndrome in 2023, requesting additional efficacy data. Multiple clinical trials ongoing for other mitochondrial indications.

Related peptide comparisons

epithalon vs mots-cfox04-dri vs mots-cmots-c vs n-acetyl-epitalonmots-c vs nad-plusepithalon vs ss-31fox04-dri vs ss-31

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free